Developing novel treatments for mood disorders: accelerating discovery.

Tamminga CA, Nemeroff CB, Blakely RD, Brady L, Carter CS, Davis KL, Dingledine R, Gorman JM, Grigoriadis DE, Henderson DC, B Innis RB, Killen J, Laughren TP, McDonald WM, M Murphy GM, Paul SM, Rudorfer MV, Sausville E, Schatzberg AF, Scolnick EM, Suppes T
Biol Psychiatry. 2002 52 (6): 589-609

PMID: 12361670 · DOI:10.1016/s0006-3223(02)01470-1

This review was generated from discussions by the Pharmacologic and Somatic Treatments Section of the National Institute of Mental Health Strategic Plan for Mood Disorders Committee on advancing novel pharmacologic and somatic treatments for mood disorders. The opening section of the article summarizes in broad strokes, current pharmacologic treatments, and new directions in the field. Thereafter the topics focus on specific research initiatives that could advance the current therapeutics for mood disorders including new basic and clinical research in vivo human imaging procedures, somatic therapeutics, and the vast new area of pharmacogenetics. New scientific and technical opportunities exist today based on advances in basic neuroscience, opportunities in clinical testing, industry interest in advancing central nervous system therapeutics, and on active consumer advocacy groups. The question of how to bring all of these positive forces together to accelerate discovery in mood disorder thera-peutics is the topic of this article.

MeSH Terms (14)

Animals Antidepressive Agents Behavioral Research Brain Clinical Trials as Topic Diagnostic Imaging Financing, Government Genetics, Behavioral Humans Mood Disorders National Institute of Mental Health (U.S.) Pharmacogenetics Research United States

Connections (2)

This publication is referenced by other Labnodes entities: